Flerie ABFRA:1NP1 27 EBITDA Margin % is 0.00% as of Mar. 2026. GuruFocus rates FRA:1NP1 with a GF Score™ of 27/100. The stock has 1 warning sign investors should review. Among 942 Biotechnology companies, Flerie AB ranks worse than 97.88% on this metric.
EBITDA Margin % is calculated as EBITDA divided by its Revenue. Flerie AB's EBITDA for the
three
months ended in Mar. 2026 was €-5.21 Mil. Flerie AB's Revenue for the
three
months ended in Mar. 2026 was €0.00 Mil. Therefore, Flerie AB's EBITDA margin for the quarter that ended in Mar. 2026 was 0.00%.
Flerie AB (FRA:1NP1) EBITDA Margin % Explanation
EBITDA Margin % is the ratio of EBITDA divided by net sales or Revenue. It is an performance metric measuring company's operating profitability. EBITDA Margin takes depreciation and amortization, interest expense and tax into account, which makes it easy to compare the relative profitability of companies of different sizes in the same industry.
Flerie AB EBITDA Margin % Related Terms
Flerie AB EBITDA Margin % Historical Data
* Premium members only.
The historical data trend for Flerie AB's EBITDA Margin % can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
FRA:1NP1 vs VRTX, REGN, ALNY: EBITDA Margin % Comparison
For the Biotechnology subindustry, Flerie AB's EBITDA Margin %, along with its competitors' market caps and EBITDA Margin % data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Flerie AB EBITDA Margin % vs Biotechnology Industry
For the Biotechnology industry and Healthcare sector, Flerie AB's EBITDA Margin % distribution charts can be found below:
* The bar in red indicates where Flerie AB's EBITDA Margin % falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Flerie AB (FRA:1NP1) has a EBITDA Margin % of 0.00% as of Mar. 2026. EBITDA Margin is the ratio of EBITDA divided by net sales or Revenue, usually presented in percent. View historical data on Flerie AB and its competitors. According to the industry distribution chart, Flerie AB ranks #922 out of 942 companies in the Biotechnology industry, placing it in the top 97.9%.
Is Flerie AB's EBITDA Margin % too high?
Flerie AB's current EBITDA Margin % is 0.00%. Based on the distribution chart, Flerie AB ranks #922 out of 942 companies in the Biotechnology industry, which is in the bottom quartile relative to peers. Overall, Flerie AB has a GF Score™ of 27/100, reflecting its overall financial health beyond just this single metric.
How does Flerie AB's EBITDA Margin % compare to VRTX and REGN?
According to the Biotechnology industry distribution chart, Flerie AB ranks #922 out of 942 companies for EBITDA Margin %. This places Flerie AB in the lower half of its industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good EBITDA Margin % for a Biotechnology company?
A good EBITDA Margin % depends on the Biotechnology industry context. However, EBITDA Margin % should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high EBITDA Margin % mean?
A high EBITDA Margin % can signal that a stock is expensive relative to its fundamentals. EBITDA Margin is the ratio of EBITDA divided by net sales or Revenue, usually presented in percent. View historical data on Flerie AB and its competitors. Flerie AB's current EBITDA Margin % is 0.00%. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Flerie AB stock overvalued right now?
Flerie AB (FRA:1NP1) has a current EBITDA Margin % of 0.00%. The current EBITDA Margin % is 0.00%. Flerie AB's overall GF Score™ is 27/100 with 1 warning sign to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is EBITDA Margin % calculated?
EBITDA Margin % is calculated from a company's financial statements. For Flerie AB (FRA:1NP1), the current EBITDA Margin % is 0.00% as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Flerie AB is a pharmaceutical company focusing on immunological diseases with great medical needs for new treatment options. The portfolio of the company includes Immuno-Oncology, metabolic diseases, and biologics development and manufacturing organizations. It operates in two segments The Product Development segment, and The Commercial Growth segment. The Product Development segment consists of early and mid-stage biotech and pharma companies advancing their products and technologies toward clinical proofof-concept and marketing approvals. The Commercial Growth segment consists of companies already selling products or services, showcasing their ability to generate increasing revenues ahead of reaching sustainable profitability.
27GF Score
Get the complete analysis for FRA:1NP1
EBITDA Margin % is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
FRA:1NP1 has been successfully added to your 
